Search results
403 results found
What does ‘good governance’ look like for genome editing?BlogPHG Policy Analyst, Tanya Brigden, usefully summarises the recommendations for the WHO's considerations towards genome editing
Expanding the public and patient role in medical regulationBlogA recent consultation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) indicates a welcome new direction for public and patient involvement (PPI).
Making the UK a science superpower – will policy moves pay off for health?BlogThe recent and abrupt change in Secretary of State for Health for the UK has overshadowed some very significant policy developments over the last week.
Calls to review regulation of direct-to-consumer genetic testingBlogExcellent new report from Science and Technology Committee, which is gratifyingly in line with our own recommendations.
Putting Genome UK into practice: genomic healthcare strategy implementationBlogImplementation plans for the UK’s landmark Genome UK strategy have been released, with specific commitments for all the major players in genomics research and healthcare revealed.
Bringing order to polygenic score reportingBlogInconsistencies in the way polygenic score models are reported could delay their introduction into healthcare.
Unpacking polygenic scoresPolicy briefingPHG Foundation has published a series of on-point briefings to help you get to grips with polygenic scores, describing and providing solutions to some of the key challenges in this field
Functional genomicsPolicy briefingAcross these two policy briefings, we outline what functional genomics is, the approaches used in this field and explore the potential impact of functional genomics on clinical medicine.
Somatic genome editing: an overviewPolicy briefingThree briefings examining somatic genome editing, the potential clinical impact of this technology, and the ethical and regulatory considerations surrounding current and future use in healthcare.
Putting AI to work in genomic medicinePolicy briefingArtificial intelligence (AI) offers great opportunities to advance genomic medicine, but enthusiasm for these technologies must be matched with collective commitment and investment to tackle serious issues posed by their use in healthcare. A set of policy briefings exploring some of those issues and how to address them